Olanzapine Instant Eg

Olanzapine, the active ingredient in Olanzapine Instant Eg, is an atypical antipsychotic presented as a strength/form for oral use. It treats schizophrenia and bipolar I disorder in adults and adolescents. GNH USA supplies Olanzapine Instant Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olanzapine Instant Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is an atypical antipsychotic that modulates neurotransmitter activity in several psychiatric conditions.

- Schizophrenia: helps reduce positive and negative symptoms and prevents relapse. - Bipolar I disorder (manic episodes): assists in controlling mood swings and stabilising manic symptoms. - Bipolar I disorder (maintenance): supports long‑term mood stabilization to reduce recurrence of episodes. - Schizoaffective disorder: alleviates combined psychotic and mood symptoms. - Psychotic depression: augments antidepressant therapy by addressing psychotic features. - Autism‑related irritability: reduces aggression and self‑injurious behaviour.

Olanzapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Weight gain: increased appetite and caloric intake. - Sedation: drowsiness or feeling of being slowed down. - Dry mouth: reduced salivation. - Constipation: decreased bowel motility. - Elevated triglycerides: rise in blood lipid levels. - Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: involuntary, repetitive movements, often of the face. - Hyperglycaemia: significant increase in blood glucose, may precipitate diabetes. - Seizures: risk of convulsive episodes. - Agranulocytosis: severe reduction in white‑blood cell count. - Hepatotoxic :   

Olile?  

-  C  

****